F

Fluidigm Corp
F:FLB

Watchlist Manager
Fluidigm Corp
F:FLB
Watchlist
Price: 1.89 EUR 0.53% Market Closed
Market Cap: 700.1m EUR
Have any thoughts about
Fluidigm Corp?
Write Note

Fluidigm Corp
Stock-Based Compensation

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Fluidigm Corp
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
F
Fluidigm Corp
F:FLB
Stock-Based Compensation
$27.7m
CAGR 3-Years
21%
CAGR 5-Years
16%
CAGR 10-Years
3%
Thermo Fisher Scientific Inc
NYSE:TMO
Stock-Based Compensation
$283m
CAGR 3-Years
12%
CAGR 5-Years
9%
CAGR 10-Years
10%
Danaher Corp
NYSE:DHR
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mettler-Toledo International Inc
NYSE:MTD
Stock-Based Compensation
$19.1m
CAGR 3-Years
0%
CAGR 5-Years
1%
CAGR 10-Years
4%
Agilent Technologies Inc
NYSE:A
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
IQVIA Holdings Inc
NYSE:IQV
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Fluidigm Corp
Glance View

Market Cap
703.6m EUR
Industry
Life Sciences Tools & Services

Fluidigm Corp. is engaged in the development, manufacture, and marketing of biotechnology tools for life sciences research. The company is headquartered in South San Francisco, California and currently employs 615 full-time employees. The company went IPO on 2011-02-10. The firm operates in development, manufacturing, and commercialization of tools for life sciences research. Its technology, mass cytometry is a multiplexed solution to analyze cell-surface and intracellular proteins simultaneously in cell suspensions including blood and disassociated tissues. Its Imaging Mass Cytometry (IMC) technology allows multiplexed imaging to understand the composition of tissue microenvironments at a subcellular 1-micron resolution. The company markets technologies and life science tools, including preparatory and analytical instruments for mass cytometry, library prep, single cell genomics, and consumables, including integrated fluidic circuits (ifcs), assays, and reagents. Its analytical instruments include Biomark HD System, EP1 System, and Hyperion Tissue Imager.

FLB Intrinsic Value
0.67 EUR
Overvaluation 64%
Intrinsic Value
Price
F

See Also

What is Fluidigm Corp's Stock-Based Compensation?
Stock-Based Compensation
27.7m USD

Based on the financial report for Sep 30, 2024, Fluidigm Corp's Stock-Based Compensation amounts to 27.7m USD.

What is Fluidigm Corp's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 10Y
3%

Over the last year, the Stock-Based Compensation growth was 145%. The average annual Stock-Based Compensation growth rates for Fluidigm Corp have been 21% over the past three years , 16% over the past five years , and 3% over the past ten years .

Back to Top